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Abstract 
Liposomal drug delivery systems can protect pharmaceutical substances and control their release. 
Systemic administration of liposomes, however, often activate the innate immune system, resulting in 
hypersensitivity reactions. These pseudo-allergic reactions can be interpreted as activating the 
complement system. Complement activation destroys and eliminates foreign substances, either directly 
through opsonization and the formation of the membrane attack complex (MAC), or by activating 
leukocytes and initiating inflammatory responses via mediators, such as cytokines. In this study, we 
investigated the in vitro immune toxicity of the recently synthesized Rad-PC-Rad liposomes, analyzing 
the liposome-induced complement activation. In five human sera, Rad-PC-Rad liposomes did not 
induce activation, but in one serum high sensitivity via alternative pathway was detected. Such a 
behavior in adverse phenomena is characteristic for patient-to-patient variation and, thus, the number 
of donors should be in the order of hundreds rather than tens, hence the present study based on six 
donors is preliminary. In order to further prove the suitability of mechano-responsive Rad-PC-Rad 
liposomes for clinical trials, the production of pro-inflammatory cytokines was examined by human 
white blood cells. The concentrations of the pro-inflammatory cytokines, IL-6, IL-12p70, TNF- a, and 
IL-1 b, induced by Rad-PC-Rad liposomal formulations, incubated with whole blood samples, were 
smaller or comparable to PBS (negative control). Because of this favorable in vitro hemocompatibility, 
in vivo investigations using these mechano-responsive liposomes should be designed.i
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Graphical Abstract: The mechano-
responsive Rad-PC-Rad liposomes, 
designed to deliver a vasodilator drug 
to stenosis, are stable even at elevated 
body temperatures. The question is 
whether these nano-containers with a 
specific shape present adverse effects 
similar to liposomal drugs in vitro or 
they don’t. 
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Purpose and Rationale 
The artificial diamidophospholipid Rad-PC-
Rad has been synthesized recently [1]. Rad-PC-
Rad liposomes aim to preferentially deliver the 
vasodilator molecules to the stenosed parts of 
blood vessels. Liposomes, administered 
intravenously, are immediately exposed to a 
complex environment of blood cells and 
proteins. The adsorption of plasma proteins on 
the surface of liposomes may not only decrease 
the therapeutic efficiency and biodistribution, 
but also may result in immunotoxicity. The 
toxicities which represent the most common 
safety issues and reasons for nanomedicines 
failure include complement-mediated reactions 
and cytokine-mediated inflammation, which 
can result in anaphylaxis. Therefore, in this 
study we investigated complement activation 
and release of pro-inflammatory cytokines, 
mediated by Rad-PC-Rad liposomes. The 
immunotoxicity can be also influenced by the 
therapeutic payload or addition of surface 
ligands. Therefore, the comparison between 
nitroglycerin-loaded and drug-free liposomes, 
as well as PEGylated and non-PEGylated 
liposomes was evaluated. The physicochemical 
properties of nanomedicines are crucial to 
determine their interaction with the immune 
system. Hence, we characterized the size, zeta 
potential, and phospholipid concentration of the 
Rad-PC-Rad liposomes. 
Introduction 
The latest progress in the nanomedicine field 
has resulted in the development of smart nano-
containers for drug delivery applications, 
including liposomes. Liposomes can improve 
delivery, targeting, and therapeutic efficacy of 
the drug and, at the same time, increase the half-
life of the drug, lower its effective dose, and 
reduce toxic side effects [2, 3]. Previously, our 
research team reported on shear stress sensitive 
Pad-PC-Pad liposomes for targeted delivery of 
a vasodilator to constricted arteries [4, 5]. A 
further in vivo investigation of Pad-PC-Pad 
phospholipids was limited owing to their phase 
transition temperature at 37 o C. Very recently, 
we have reported on a more thermally stable 
phospholipid formulation, such as Rad-PC-Rad 
[1]. This lipid exhibits a bilayer main phase 
transition temperature of 44.7 °C and preserves 
the responsiveness for mechanical triggers [1]. 
The immediate treatment of arterial occlusion 
generally involves intravenous injection of 
nitroglycerin (NTG), which acts as a 
vasodilator. Systemic administration of NTG 
may cause severe adverse effects including 
hypotension and diminished blood perfusion to 
the heart. The targeted delivery of NTG via the 
incorporation into shear stress sensitive 
liposomes may reduce these side effects. The 
direct contact of liposomes with blood carries 
the risk of immediate activation of the innate 
immune system [6]. This may result not only in 
the reduction of the drug’  s efficacy, but also 
in the appearance of hypersensitivity reactions 
(HSRs) [6-8]. The main function of the immune 
system is to protect the organism from invading 
pathogens. It can, however, also develop an 
immune response against non-pathogenic 
objects, such as nanometer-size liposomes. 
Therein, the recruitment of the complement 
system is an important step in the recognition 
and elimination of foreign materials. The 
complement system is a group of 
approximately 30 plasma- and membrane-
bound proteins [9]. Their protective function 
leads to the release of active components, which 
cause opsonization, inflammation, and the 
generation of the membrane attack complex 
(MAC) [10]. According to the current literature, 
the complement activation occurs via the three 
established routes: classical, lectin, and 
alternative pathways [10]. One can discriminate 
between these pathways by identifying the 
presence of unique protein fragments: C4d 
(classical and lectin pathways) and Bb 
(alternative pathway) [11]. Activation of either 
pathway results in the turnover of the C3 
protein, which is followed by the production of 
the anaphylatoxins C3a and C5a, and the 
formation of the MAC (C5b-9). The release of 
anaphylatoxins causes leukocyte chemotaxis 
and the production of pro-inflammatory 
cytokines, which finally induce inflammation 
(Figure 1). The excessive production of 
anaphylatoxins can be harmful and may cause 
anaphylactic shock or even organ failure at 
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relevant concentrations [12]. Binding of the 
proteins to the liposomes depends also on their 
composition, size, geometry, surface charge, 
and hydrophobicity that can act as 
immunological adjuvant and trigger strong 
immune response [6, 13]. The undesirable 
activation of the complement system can be 
caused by systemically administered liposomes, 
such as Doxil® (PEGylated liposomal 
doxorubicin) and AmBisome® (liposomal 
amphotericin B), leading to the development of 
HSRs, termed complement activation-related 
pseudoallergy (CARPA) [7, 8]. Approximately 
2–10% of patients may adversely react to 
intravenously administered liposomal 
formulations with mild-to-severe 
hypersensitivity reactions [8]. CARPA 
develops at the first exposure and its symptoms 
involve almost all organ systems [14]. Some of 
the most important safety concerns for 
nanoparticle failure are related to the toxicities 
caused by complement activation-mediated 
reactions and cytokine-mediated inflammation 
[15]. Therefore, it is recommended that 
liposomes intended for intravenous injection 
are tested in vitro and in vivo for the potential 
activation of complement system, as a 
preclinical immune toxicity test [16]. The 
assessment of the liposomal physicochemical 
properties and their impact on complement 
activation is also an important objective in the 
development of nanometer-size therapeutics. 
The production of pro-inflammatory cytokines 
in vitro is considered a marker of cytokine-
associated immunotoxicity in vivo [15] and 
screening for these toxicities early in preclinical 
characterization will help to avoid potentially 
toxic candidates in nanomedicine development. 
Recently, Wolf-Grosse et al. reported about 
cytokine secretion in a complement-dependent 
manner [17]. They state that cytokine response 
was generally mostly due to C5a activation, as 
it is the most potent pro-inflammatory mediator 
released upon C activation [17]. Therefore, in 
order to prevent the potential immunotoxicity 
in vivo, we studied the effect of Rad-PC-Rad 
liposomes on the production of complement 
proteins and pro-inflammatory cytokines. 
Experimental design 
In the present article, we address the 
possibilities that Rad-PC-Rad liposomes, 
loaded with NTG solution, would activate the 
complement system and stimulate the release of 
pro-inflammatory cytokines, thus raising 
concern about potential risk for CARPA or 
cytokine storm. Thus, we have measured in 
vitro complement activation in human sera and 
the release of the pro-inflammatory cytokines, 
in human whole blood and isolated leukocytes, 
upon incubation with Rad-PC-Rad liposomes. 
The complement pathway activation products 
C4d and Bb, and terminal complement complex 
SC5b-9 were measured using an enzyme linked 
immunosorbent assay (ELISA), and the release 
of the pro-inflammatory cytokines IL-1b, IL-6, 
IL-8, IL-12, TNF-α  was measured using a 
cytometric bead array test. In addition, we 
analyzed the liposomal physicochemical 
properties, in terms of liposomes size and zeta 
potential, using dynamic light scattering (DLS), 
and estimated membrane thickness from the 
micrographs, obtained by cryogenic 
transmission electron microscopy (cryo-TEM). 
Materials and Methods 
Materials 
1,3-Diheptadecanamidopropan-2-yl (2-
[trimethylammonio]ethyl) phosphate (Rad-PC-
Rad) was synthesized and purified according to 
the recently reported protocol [1]. Figure 2 
shows the structural formula of the Rad-PC-
Rad phospholipid. Table S1 lists all the 
materials used for the experiments. 
Human sera from six healthy volunteers and 
whole blood samples from two healthy donors 
were obtained through an institutionally 
approved phlebotomy protocol at Semmelweis 
University (Budapest, Hungary). Human sera 
were stored at a temperature of −80 °C until 
usage. Whole blood samples were freshly 
collected into sterile hirudin-treated tubes and 
immediately employed for experiment. Freshly 
drawn blood, used for leukocytes isolation, was 
provided by the Hungarian National Blood 
Transfusion Service.
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Figure 1. Schematic representation of complement (C) activation triggering pro-inflammatory cytokines due to anaphylatoxin 
binding to anaphylatoxin-receptor positive cells (e.g., mast cells, basophils, neutrophils, platelets and pulmonary 
intravascular macrophages). In the case of Rad-PC-Rad liposomes, C activation proceeds through the alternative pathway. 
On this pathway C3 directly binds to liposomal phospholipid head-groups. Factor B binds to the newly attached C3b, and 
again becomes susceptible to cleavage by factor D. Membrane-bound C3bBb is unstable until it is bound by properdin protein 
(factor P). Stabilized C3-convertase rapidly generates large amounts of C3b that bind more factor B, resulting in dramatic 
amplification of C3b. Membrane-bound C3b serves as an opsonin and a binding tag for phagocytic cells. Addition of C3b to 
C3-convertase results in the formation of C5-convertase, which cleaves C5 into C5b, and proceeds to form the MAC. Cleavage 
of C5 also results in the formation of C5a anaphylatoxin. Together with C3a, the C5a fragment binds to the surface C receptors 
of mentioned allergy mediating cells. C3a and C5a receptors, after binding small anaphylatoxins, mediate the allergic reaction 
by stimulating the release of vasoactive mediators (e.g., histamine, thromboxanes, leukotrienes, etc.). 
Liposome preparation 
Four Rad-PC-Rad/DSPE-PEG2000 phospho-
lipid formulations were prepared, namely R1, 
R2, R3, and R4 (see Table 1). Lipids were 
dissolved in chloroform in molar ratios as listed 
in Table 1. The preparation of the liposomal 
formulations is described in detail in ref. [18]. 
The samples were purified through sterile 
filters and stored at a temperature of 4 °C until 
usage. 
Characterization of liposomal 
formulations 
Phospholipid concentration. A colorimetric 
assay (phosphate test 2.0) [19] was used for the 
determination of the phospholipid content of 
the liposomal formulations after extrusion and 
purification. Here, the phosphate moiety in the 
head group of the phospholipids was a measure 
of the total phospholipid concentration. 
Table 1. Composition of Rad-PC-Rad 
liposomal formulations 
Label 
Lipid composition 
(molar %) Loading 
buffer Rad-PC-
Rad 
DSPE-
PEG2000 
R1 100 - saline 
R2 95 5 saline 
R3 100 - NTG 
R4 95 5 NTG 
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To exclude the variations in lipid concentration, 
the concentration of each liposomal 
formulation (R1, R2, R3, and R4) was diluted 
with 0.9% sodium chloride solution (saline) to 
a total lipid concentration of 10 mg/mL. In 
addition, a set of the diluted formulations (R1d, 
R2d, R3d, and R4d) with 5 mg/mL of 
phospholipids were prepared for the in vitro 
immunoassays to examine the impact of the 
lipid concentration on the complement 
activation level (see Figures S2 and S3).  
Physicochemical characteristics. The liposome 
average diameter, polydispersity index (PDI) 
and zeta (z) potential were obtained by DLS 
performed at a temperature of 25 °C using a 
DelsaMax PRO (Beckman Coulter, USA). The 
suspensions were diluted 100 times in saline 
prior to the measurements. 
Liposome morphology. The morphology of four 
Rad-PC-Rad formulations was studied using 
cryogenic transmission electron microscopy 
(cryo-TEM) (JEM2200FS, JEOL, Tokyo, 
Japan). The samples, diluted with saline in the 
ratio 1:1, were imaged as previously reported [1, 
18]. 
Encapsulation efficiency. The encapsulation 
efficiency of Rad-PC-Rad liposomes for 
passive loading with nitroglycerin was 
determined indirectly by measuring the peak of 
a glucose-trifluoroacetic acid adduct by 
electrospray ionization mass spectrometry 
(ESI-MS) on a Bruker esquire HCT ion trap 
mass spectrometer (Bruker Corporation, USA) 
[18]. 
Liposomal release. Two Rad-PC-Rad 
liposomal formulations, i.e. with and without 
DSPE-PEG, were loaded with 5(6)-
carboxyfluorescein (CF) buffer, and prepared 
as described in ref. [1]. Seven aliquots with a 
volume of 2 mL were separated into 5 mL glass 
vials and kept for selected periods of time (0, 5, 
10, 20, 40 min) at a temperature of 37 °C. The 
CF release was quantified using a 
fluorospectrometer (SpectraMax 2, Bucher 
Biotec AG, Switzerland) with the wavelengths 
of 485 nm for excitation and 538 nm for 
emission. Sample fluorescence at a temperature 
of 20 °C served as a negative control (F0). As a 
positive control for the maximum dye release 
(F100), liposomal samples were heated to a 
temperature of 65 °C, above the lipids 
transition temperature of 44.7 °C. The release 
fraction at the selected time point x was 
calculated according to: 
𝑅𝑒𝑙𝑒𝑎𝑠𝑒(%) =
𝐹, − 𝐹-
𝐹.-- − 𝐹-
 
where 𝐹, is the fluorescence at time x. 
Complement immunoassay 
Activation of human sera with liposomes. 
Human sera from six healthy donors were 
thawed and kept at a temperature of 4 °C 
during the experiment. Due to the limited 
amount of serum available, the sera #5 and #6 
were prepared as pools from distinctive donors 
in the ratios 1.5:1 and 7.8:1, respectively. The 
liposomal suspensions in the two 
concentrations were added to the sera of each 
donor in the ratio of 1:3. Saline and 
nitroglycerin were used as negative controls. 
FDA-approved liposomal drugs, with recorded 
cardio-toxicity effects and activation of the 
complement system in sensitive patients, 
Doxil® (2 mg/mL doxorubicin, 12.77 mg/mL 
phospholipids, used as provided) and 
AmBisome® (17.975 mg/mL amphotericin B, 
4.02 mg/mL phospholipids, reconstituted with 
injection water) were employed as well [7]. 
Zymosan (1.2 mg/mL), known as activator of 
the complement system, was used as positive 
control. Each activation mixture was incubated 
at a temperature of 37 °C. The concentration 
of the terminal complement complex SC5b-9 
was investigated over time. The incubation was 
terminated after 5, 10, 20, and 40 minutes by 
adding 10 mM EDTA. 
ELISA immunoassays 
The ELISA assays were carried out following 
the manufacturer’ s protocol. The optical 
density was measured with a 96-well plate 
reader (FLUOstar Omega, BMG Labtech, 
Germany) at a wavelength of 450 nm for SC5b-
9, Bb, C3a and C5a as well as at a wavelength 
of 405 nm for C4d. 
Cytokine immunoassay 
Isolation of leukocytes from buffy coat. A 
volume of 400 mL of buffy coat (BC), a pool of 
white blood cells (WBCs) concentrates of four 
healthy volunteers, were obtained from the 
Hungarian National Blood Transfusion Service 
within 24 hours of blood withdrawal. 
Altogether three BC pools were used, each 
consisting of four donors. Leukocytes were 
further concentrated two times by mixing with 
DPBS (w/o CaCl2, MgCl2) in 1:1 ratio and 
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centrifuged for a period of ten minutes at a 
velocity of 750 G and a temperature of 4 °C. 
To lyse the remaining erythrocytes, distilled 
water at a temperature of 4 °C was added to 
the BC (4:1 ratio) for 20 seconds. Lysis was 
stopped by adding one volume hyperosmotic 
salt solution (containing 1.8% of NaCl). After 
washing with ice-cold DPBS (w/o CaCl2, 
MgCl2) for platelets elimination, WBCs were 
re-suspended in R5 medium. 
Qualitative and quantitative analysis of 
isolated leukocytes. The concentration of 
WBCs, in three independent blood packages 
was determined. Viable cells were detected 
using FITC Annexin V apoptosis detection kit, 
see Table S4. The staining procedure was 
performed according to the manufacturer’s 
instructions. Leukocytes were further diluted or 
concentrated to reach the necessary 
concentration of ~108 cells/mL. The cell 
viability was also checked after cell isolation 
and treatments by test materials and control 
agents. The viability of cells before and after 
treatments were always higher than 98%, 
except for the positive control, Table S5. 
Activation of BC leukocytes with liposomes. 
Freshly isolated leukocytes from three 
independent blood packages were separately 
incubated with four Rad-PC-Rad liposomal 
formulations in the ratio 7:1. Samples, with a 
concentration of 4 mg/mL, were incubated for 
four hours at a temperature of 37 °C on a 
shaker plate. The incubation was stopped by 
EDTA (final concentration 10 mM). Cell 
culture supernatants were further used for 
mixing with cytokine capture beads. The assay 
was performed according to the suggested 
protocol the manufacturer provided with the kit. 
Activation of human whole blood with 
liposomes. Freshly collected whole human 
blood from two donors was separately 
incubated with four Rad-PC-Rad liposomal 
formulations at a concentration of 4 mg/mL, 
following the same procedure as described in 
the section above. The distinctive step was the 
incubation time. Here samples were incubated 
for a period of six hours. Whole blood samples 
had no R5 medium, instead they contained their 
own plasma. 
Qualitative and quantitative analysis of 
leukocytes originated from whole blood 
samples. An aliquot of human blood from two 
donors was stained as described in the section 
above. Cell viability was determined before and 
after treatments by test materials and control 
agents. The percentage of viable cells was more 
than 97%, except for the positive control, Table 
S5. 
Cytometric bead array test. The human 
inflammatory cytokines kit was used to 
quantitatively measure interleukin-1b (IL-b), 
interleukin-6 (IL-6), interleukin-8 (IL-8), 
interleukin-12p70 (IL-12p70), tumor necrosis 
factor α (TNF-α), and interleukin-10 (IL-10) 
protein levels in the studied samples. The assay 
was carried out following the manufacturer’s 
instructions. The beads fluorescence was 
recorded by flow cytometry using a FACScan 
instrument (BD Biosciences, USA), and the 
data were analyzed using the Kaluza Analysis 
1.5 software (Beckman Coulter, USA). 
Statistical analysis 
Statistical analysis was carried out using 
GraphPad Prism 6 (GraphPad Software Inc., 
USA). Data from the ELISA samples (Figures 
4 and 7), except zymosan, were compared with 
saline as negative control after 40 minutes of 
incubation. Significance of differences between 
the groups was determined by non-parametric 
Kruskal-Wallis test, followed by Dunn's 
multiple comparisons test. P-values lower than 
0.05 were considered as statistically significant. 
Results 
Characterization of Rad-PC-Rad liposomal 
formulations 
The lipid concentration of Rad-PC-Rad ranged 
from 10 to 20 mg/mL, and the mean diameter 
of the liposomes in the suspensions was around 
100 nm and varied from 95 to 140 nm (see 
Table 2). Measurements after 20 days showed 
that the PEGylated liposomes did not change 
their size, whereas the non-PEGylated ones 
displayed an increase from 140 to 270 nm (R1) 
and from 115 to 200 nm (R3). 
Table 2 lists the measured zeta potential values 
of the Rad-PC-Rad formulations. Pure Rad-PC-
Rad samples revealed positive z potential 
values, between +1.3 (R1) to +4.7 mV (R3), 
while PEGylated samples turned to negative 
potentials, from −2.0 (R4) to −4.5 mV (R2).  
The size and morphology of Rad-PC-Rad 
liposomes, evaluated using cryo-TEM imaging, 
is represented in Figure 2. These micrographs 
show intact spherical, lenticular, and faceted 
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unilamellar liposomes below their main phase 
transition temperature. The percentage of 
faceted liposomes within samples was 46% 
(R1), 72% (R2), 42% (R3), and 52% (R4).
Table 2. Characteristics of Rad-PC-Rad liposomal formulations. 
Label Lipid composition 
Lipid 
content 
(mg/mL) 
Mean 
diameter 
(nm)* 
PDI* 
Membrane 
thickness 
(nm) 
z potential 
(mV)* 
R1 Rad-PC-Rad (saline) 10.17 ± 0.02 138.6 ± 3.5 0.15 ± 0.03 3.27 ± 0.14 +1.29 ± 0.37 
R2 
Rad-PC-
Rad/DSPE-
PEG2000 (saline) 
18.39 ± 0.13 106.5 ± 1.9 0.14 ± 0.02 3.60 ± 0.21 −4.52 ± 1.05 
R3 Rad-PC-Rad (NTG) 13.62 ± 0.72 114.5 ± 0.4 0.06 ± 0.03 3.27 ± 0.19 +4.65 ± 0.42 
R4 
Rad-PC-
Rad/DSPE-
PEG2000 (NTG) 
21.75 ± 3.35 97.0 ± 0.6 0.12 ± 0.01 3.50 ± 0.24 −2.08 ± 0.51 
* Data were recorded immediately after sample preparation. 
 
The addition of DSPE-PEG (see Figure 2D and 
2F), led to the co-existence of flat circular disks 
and unilamellar liposomes. Depending on the 
disk orientation, they appear either as small 
rods with high contrast (red-colored arrows), or, 
when seen from the top, as circular structures 
with low uniform contrast (Figure 2D, right). 
The liposome membrane thickness was 
estimated from the cryo-TEM projections of the 
appropriately oriented membranes (Figure 2). 
We have measured the individual thicknesses 
of 100 membranes and found the mean values 
of R1 to be (3.27 ± 0.14) nm and of R3 to be 
(3.27 ±  0.19) nm, which indicates the 
interdigitation of the Rad-PC-Rad leaflets. 
Interdigitation may be one of the driving forces 
in the formation of faceted liposomes [1]. 
Samples loaded with DSPE-PEG, i.e. R2 and 
R4, tended to result in higher mean values. The 
values correspond to (3.60 ±  0.21) nm and 
(3.50 ±  0.24) nm, respectively. The mean 
diameters of the liposomes, derived from cryo-
TEM images, were 10–15% smaller than those 
obtained from DLS data.  
The encapsulation efficiency of NTG-loaded 
samples was estimated from the ESI-MS 
measurements. The calculation is based on the 
100% ESI-MS signal of pure NTG and 
liposome size. The employed NTG solution 
contained glucose as an excipient, therefore, the 
NTG encapsulation was determined indirectly. 
The integral of the glucose-trifluoroacetic acid 
adduct was evaluated after NTG incorporation. 
The ratio between these values determines the 
percentage of NTG encapsulation efficiency 
(see Table S2). The values correspond to 38% 
(R3) and 12% (R4). 
In order to measure the membrane permeability, 
a release test of CF-loaded liposomes at a 
temperature of 37 °C was performed under 
static conditions (Figure 3). Both, Rad-PC-Rad 
and Rad-PC-Rad/DSPE-PEG samples 
demonstrated an immediate spontaneous 
release of 17% and 8% CF, respectively. 
During another 40 minutes of incubation the 
release level increased to 36% (Rad-PC-Rad) 
and 33% (Rad-PC-Rad/DSPE-PEG). The initial 
CF release trend line of both samples was 
distinctive, however after 25 minutes the 
spontaneous release level of the two 
formulations was comparable and reached 
about 35%. 
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Figure 2. The structure of the two phospholipids used for the liposome preparation: Rad-PC-Rad (A) and DSPE-PEG (B). 
Cryo-TEM micrographs of the liposomal formulations: R1 (C), R2 (D), R3 (E), R4 (F). Scale bars are 100 nm. The samples 
contain spherical and faceted liposomes. The incorporation of DSPE-PEG caused the formation of bicelles indicated by the 
red-colored arrows. 
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Figure 3. The release of 5(6)-carboxyfluorescein 
containing liposomes formulated from Rad-PC-Rad and 
Rad-PC-Rad/DSPE-PEG. The samples were heated to a 
temperature of 37 °C and kept at constant temperature 
for a period of 0, 5, 10, 20, and 40 minutes. The final 
spontaneous CF release was about 35%. The data are 
represented as mean values, error bars indicate standard 
deviation (n = 5). 
Complement immunoassays 
Figure 4A displays the level of SC5b-9 (TCC), 
which is a marker for the activation of the 
complement system. The mean values of the six 
donors demonstrate that the liposomal 
formulations R1 and R3 have caused an eleven- 
and 15-fold increase in SC5b-9 concentration in 
comparison to the negative control (saline), 
whereas R2 and R4 have raised the SC5b-9 
concentration by a factor of eight or nine, 
respectively. Noticeably, Donor #5 (gray 
hexagonal) showed a tremendous increase of 
TCC in the four Rad-PC-Rad liposomal 
formulations, which largely contributed to the 
increased mean values of each liposomal 
sample. The increase of SC5b-9 was at the same 
level with its positive control, namely about 28-
fold compared with saline (Table S3). Certainly, 
the contribution of Donor #5 into the mean 
value of all six donors, caused a deviation of 
mean values up to four times. Doxil® and 
AmBisome® samples did not reveal a 
substantial difference in the level of SC5b-9 
between the six donors. Doxil® samples showed 
less than two-fold increase, while AmBisome® 
demonstrated more than nine-fold elevation of 
the TCC protein compared to saline. Zymosan 
caused a considerably high level of 
complement activation, namely 55-fold, and 
was excluded from the diagrams to present the 
differences between the tested samples in a 
clearer way. Our findings were statistically 
confirmed. NTG, which was chosen as another 
negative control, was compared to saline and no 
statistical difference was identified. R1 and R3 
samples showed very significant to extremely 
significant differences compared to the 
negative control. In contrast, the samples R2 
and R4 did not reveal a statistically significant 
difference versus saline. The SC5b-9 level 
caused by Doxil® among the six sera, showed 
no statistical difference compared to saline. 
Certainly, AmBisome® was detected to be 
extremely significant towards the negative 
control. 
Figure 4B demonstrates the level of C4d protein, 
which is an experimental marker for the 
activation of the classical and the lectin 
pathways. Neither the Rad-PC-Rad liposomes, 
nor the FDA-approved liposomal formulations 
revealed a significant increase of C4d protein 
concentration. The mean values show a less 
than four-fold increase in comparison to the 
negative control. 
Figure 4C represents the level of Bb fragment 
as an experimental marker for alternative 
complement system activation. The serum from 
Donor #5 towards Rad-PC-Rad liposomal 
formulation showed four to eight-fold elevation 
of Bb concentration, whereas the other five 
donors demonstrated less than three-fold 
increase compared to saline. All six sera were 
similarly sensitive to the AmBisome® with an 
increase of four times above the negative 
control, revealing a strong statistical 
significance. A significant serum reactivity 
towards Doxil® was not observed. 
The detection of C3a (Figure 4D) revealed no 
significant difference between the highly 
sensitive donor and the others. Most of the 
values were within the error bars. Rad-PC-Rad 
liposomes and Doxil® showed values between 
two- and three-times higher in comparison to 
saline, while AmBisome® caused an elevation 
of C3a similar to that one of the positive control 
– a three- to four-fold increase. 
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Figure 4. The concentration of SC5b-9 (A), C4d(B), Bb (C), C3a (D), and C5a (E) complement proteins. Human sera from six 
independent donors were incubated for a period of 40 minutes at a temperature of 37 °C with saline, nitroglycerin (NTG), 
Rad-PC-Rad liposomal suspension of selected composition (R1, R2, R3, R4), Doxil® and AmBisome®. Saline solution was 
chosen as negative control. NTG was used as another negative control. Non-PEGylated liposomal formulations caused a 
higher level of C activation, mainly via the alternative pathway. Highly sensitive serum towards artificial Rad-PC-Rad 
liposomes was identified. This activation of the C cascade resulted in the increased production of C5a anaphylatoxin. The 
positive control zymosan caused substantially higher levels of complement activation. The data are represented as median, 
including error bars derived from the interquartile range among six donors. Each symbol and color represents data from a 
single donor. Significance of differences among the groups was determined by non-parametric Kruskal-Wallis test, followed 
by Dunn's multiple comparisons test. P-values lower than 0.05 were considered as statistically significant.
Precisionnanomedicine.com DOI: 10.29016/180419.2   Andover House, Andover, MA USA  
 The official Journal of CLINAM 52 
 
Figure 5. Concentration of pro-inflammatory cytokines IL-6 (A), IL-12p70 (B), TNF-α (C), and IL-1b (D) induced by Rad-
PC-Rad liposomal formulations (R1-R4) incubated with whole blood samples from two donors (first donor: left panels, second 
donor: right panels) for a period of six hours at a temperature of 37 °C. PBS was chosen as negative control. The effect of 
Rad-PC-Rad liposomes upon production of cytokines was lower or comparable to the negative control. Less than two-fold 
increase in the IL-12p70 concentration was observed by R1 treatment (first blood sample). The second blood sample revealed 
a highly elevated concentration of IL-12p70 induced by R2. IL-1b concentration of the second donor’s blood was close to 
the detection limit of the kit. The positive control zymosan caused a considerably high level of complement activation, which 
was mostly above the top standard concentration and was therefore excluded from the graph. The data represent a single 
value from each donor. 
For the activation of SC5b-9, Bb, and C3a, 
Donor #5 demonstrated a similar trend, where 
the reactivity towards Rad-PC-Rad samples 
was higher for the R1 and R3 samples 
compared to R2 and R4. 
Donor #5 showed a significant increase in C5a 
concentration in comparison to the other five 
donors (Figure 4E). The values were elevated 
17- to 21-fold above the negative control, and 
the trend was distinctive from the one 
previously observed (SC5b-9, Bb and C3a). 
Here, sample R2 revealed the highest C5a level, 
whereas R1, R3 and R4 were similar. The 
increase of the C5a concentration detected by 
the other five donors was below four times the 
baseline for the Rad-PC-Rad samples and 
Doxil®, while AmBisome® displayed a four-
fold increase 
Cytokine immunoassay 
The concentration of the inflammatory 
cytokines is listed in Table S6: IL-6, IL-12p70, 
TNF-α, IL-1b, IL-10 and IL-8. Figures 5 and 
6 represent the levels of the identified pro-
inflammatory cytokines in whole blood and BC 
cells, respectively, caused by Rad-PC-Rad 
liposomal formulations. 
The concentration of each cytokine was 
compared to saline, which served as a negative 
control. Whole blood samples were collected 
from two donors and revealed a substantial 
difference in the sensitivity towards the studied 
samples. The effect of Rad-PC-Rad liposomal 
formulations on the production of pro-
inflammatory cytokines were lower or 
comparable to the negative control. Less than a 
two-fold increase in the cytokine concentration 
was caused by R1 and R4 samples, in case of 
IL-12p70 (first blood sample) and IL-1b 
(second blood sample), respectively, see 
diagrams in Figure 5B and 5D. The 
concentration of IL-1b (second blood sample) 
was below the detection limit of the kit (see 
Table S6). Surprisingly, the second donor 
showed a large increase in production of IL-
12p70 in response to the R2 sample, even 
higher than the positive control. However, as no 
additional donor samples were available, we 
can’t conclude the importance of this increase.
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Figure 6. Concentration of pro-inflammatory cytokines induced by Rad-PC-Rad liposomal formulations incubated with 
isolated leukocytes from three buffy coat pools, each consisting of four donors. Buffy coats were incubated with R1-R4 for a 
period of four hours at a temperature of 37 °C. PBS was chosen as negative control. The Rad-PC-Rad formulations caused 
an elevated level of IL-6 in a part of the buffy coat samples. Insubstantial elevation of IL-12p70 was identified in R2 treated 
group in each BC. The increase in the level of TNF-α was observed only in one of the buffy coats by R2 sample. The other 
Rad-PC-Rad liposomal formulations were comparable with PBS. The positive control zymosan caused a considerably higher 
level of complement activation, which was above the top standard concentration and was therefore excluded from the graph. 
The data represent a single value from each buffy coat. The label “nd” means not detected. 
 
The concentration of IL-10 was detected only 
in the samples treated with the positive control. 
The level of IL-8 gave false positive results and 
was above the top standard concentration, see 
Table S6. Therefore, it was excluded from the 
study. 
Rad-PC-Rad formulations caused an elevated 
level of IL-6, by four- to nine-fold, in one of 
three BCs compared to PBS (see Figure 6A). 
The concentration of IL-6 caused by R5 
medium, however, was comparable to the one 
caused by R1 and R4 (see Table S6). Another 
BC sample demonstrated an increased level of 
IL-6, caused only by the R1 sample. A raise in 
the IL-6 concentration caused by the third 
tested BC sample was not detected by any of the 
liposomal formulations (see Figure 6A). In case 
of IL-12p70, incubation with four Rad-PC-Rad 
formulations resulted in less than two-fold 
increase of the cytokine level (see Figure 6B). 
Moreover, in some of the cases, IL-12p70 
levels stimulated by Rad-PC-Rad liposomes 
were lower than those of the negative control. 
A surprising increase in the concentration of 
TNF-α was observed in one of the BC samples 
by R2 (Figure 6C). None of the other samples 
elicited an increase in the TNF-α cytokine. In 
case of IL-1b, only R3 demonstrated a two-fold 
increase of the cytokine above the negative 
control (see Figure 6D) whereas the other Rad-
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PC-Rad liposomes revealed an increase of IL-
1b of less than a factor of two. In summary, the 
cytokines levels caused by Rad-PC-Rad 
liposomal formulations were comparable with 
those caused by the negative control. 
Discussion 
The objective of the study was to investigate the 
immune response towards the recently 
developed artificial Rad-PC-Rad liposomes 
loaded with NTG. For this purpose, we 
measured the level of C activation markers and 
pro-inflammatory cytokines in vitro. We 
performed the physicochemical 
characterization of Rad-PC-Rad liposomes and 
discussed their potential influence upon the 
activation of the immune system. 
Characterization of Rad-PC-Rad liposomal 
formulations 
The surface charge of Rad-PC-Rad liposomal 
suspensions was characterized using the ζ -
potential, which is one of the principal 
indicators of the colloid stability. A potential of 
±  30 mV has been considered as the limit, 
above which a colloidal system becomes stable 
[20]. Rad-PC-Rad liposomes are non-charged 
nanometer-sized species with relatively low 
repulsive forces. They tend to aggregate. To 
improve the stability of the Rad-PC-Rad 
liposomes, we incorporated DSPE-PEG 
molecules into the liposomes, which cause a 
steric repulsion between lipid bilayers [21]. 
Furthermore, it resulted in the alteration of the 
ζ-potential to negative values. This alteration 
is a consequence of the negatively charged 
DSPE-PEG molecules owing to its 
phosphodiester moiety [22]. 
The morphology of Rad-PC-Rad liposomes can 
deviate from the spherical shape. The 
liposomes often exhibit irregular facets (Figure 
2). The co-existing spherical and facetted 
liposomes are two forms that may differ in the 
molecular fraction of the lipid components. 
Therefore, we have performed differential 
scanning calorimetry and found that upon 
repeated heating and cooling additional peaks 
arose (see Figure S1). This observation clearly 
indicates that various phases have become 
coexistent. The occurrence of faceted 
liposomes is explained by the formation of an 
intermolecular hydrogen-bonding network at 
the hydrophobic-hydrophilic interface of the 
lipids and membrane interdigitation, as recently 
studied for Rad-PC-Rad in detail [1]. 
The PEG-containing liposomes, R2 and R4, 
sometimes appear as flat circular disks (see 
micrographs D and F in Figure 2). In fact, these 
features originated from tilted bicelles or 
micelles [23, 24]. It should be noted that DSPE-
PEG is known as a micelle-forming species [25, 
26]. The spontaneous formation of bicelles is 
related to the phase separation between Rad-
PC-Rad and DSPE-PEG. The formation of 
bicelles without an internal cavity led to the 
decrease of NTG encapsulation by 26%. This 
shortcoming has to be addressed in future 
investigations by balancing the PEG-
incorporation to optimize the liposomes ’ 
stability and minimize bicelles formation. 
The cobblestone-like features in the micrograph 
D of Figure 2 may originate from PEGylated 
lipids, which failed to form liposomes. The 
samples have to be frozen for the cryo-TEM 
data acquisition. The higher viscosity of 
PEGylated samples results in the formation of 
thick ice, which impedes the imaging, see 
micrographs D and F of Figure 2. 
Complement immunoassays 
We examined the biological effects of Rad-PC-
Rad liposomes on C activation. C activation by 
liposomes depends on several physicochemical 
factors, including lipid composition, liposome 
size, morphology, and surface charge [27-29]. 
Larger liposomes are more prone to activate the 
complement system than smaller liposomes 
[30]. This observation explains the increased 
level of C proteins by the R1 and R3 samples, 
which diameters were larger and increased with 
time owing to aggregation. The importance of 
geometric factors on the assembly of 
complement convertases [30] or provoking 
cardiopulmonary distress in pigs [31] can also 
be a pivotal parameter in combating adverse 
reactions. The impact of geometry and topology 
on complement activation was identified by 
Moghimi et al. and Wibroe et al. [28, 31]. The 
cryo-TEM images represented in Figure 2 show 
Rad-PC-Rad liposomes with faceted and 
spherical shapes as well as disk-like PEGylated 
phospholipid-based bicelles. Therefore, the 
study on adverse reactions of rod- and disk-like 
particles reported recently [31] is of particular 
value. Even though this study reports on C-
independent adverse injection reactions, it 
clearly demonstrates the impact of the particle 
morphology on the immune cells recognition. 
The incorporation of PEG into liposomes is 
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considered to improve C compatibility and 
prolong liposomes circulation [32]. Their 
infusion, however, can give rise to HSRs [7, 33, 
34]. PEGylated liposomes are able to trigger C 
activation due to the presence of the anionic 
phosphate-oxygen moiety of the PEGylated 
phospholipid [35]. Positive or negative surface 
charge may also enhance C activation [36], for 
example by insertion of the negatively charged 
PEGylated phospholipids. Such negative ζ -
potential values were identified in the PEG-
containing Rad-PC-Rad liposomal 
formulations. The C activation-promoting 
activity of negative surface charges on 
liposomes was already discussed previously [7]. 
In our study, only minor differences were 
observed in PEGylated samples versus negative 
control. 
Another interesting phenomenon was observed, 
when drug molecules were encapsulated into a 
liposomal cavity (e.g., Doxil®, prednisolone). 
The C activation was considerably higher than 
for the liposomes of the same size and 
composition but without the entrapped drug [32, 
37]. In case of Doxil®, this phenomenon was 
explained by changes in the liposomal 
morphology arising from the drug loading 
procedures [28]. Here, we observed that NTG-
containing samples (R3 and R4) caused a 
slightly increased level of C proteins, in 
comparison to their drug-free counterparts. 
NTG alone did not have any significant impact 
on C activation (P < 0.05). 
The release test showed that 17– 36% of 
loaded buffer was spontaneously released 
during the incubation. These observations 
suggest that the drug incorporation into the 
liposomes causes physicochemical changes to 
the liposomal formulation. Together with a 
partial release of the drug it may have a 
synergistic effect on C activation. The 
frequency of HSRs from FDA-approved 
liposomal drugs varies, for example ~10% with 
Doxil® and ~30% with AmBisome® [7]. 
AmBisome®, a highly negatively charged 
liposome formulation, was found to be a very 
strong C activator [7]. AmBisome® 
significantly differs from Doxil®, which causes 
strong C activation only in certain sensitive sera. 
This feature was confirmed in our experiment. 
AmBisome® caused the formation of 
significantly higher (P < 0.05) levels of all C 
proteins (Figure 4). 
The increased level of TCC led us to determine 
the pathway of C activation. We found that the 
classical and lectin pathways were not involved 
in the C activation, but could confirm that the 
alternative pathway was involved, in agreement 
with previous results on Pad-PC-Pad liposomes 
[11]. 
It has to be noted that one of the six human sera 
showed an anomaly. This pooled serum, #5, 
was highly sensitive to the Rad-PC-Rad 
liposomes. Although the pooling of sera from 
different donors is common for in vitro studies, 
it should be handled with care and the ratio 
seems to play an important role: the volumes 
from each serum should be equal [38]. As this 
phenomenon has not been considered in the 
present study, the experimental data were 
evaluated excluding Donor #5 (see Figure 7). 
The differences between the sera provide 
evidence for the utility of in vitro C assays and 
mimic the clinical situation. HSRs are mostly 
minor and transient; however, life-threatening 
reactions can happen occasionally in a 
hypersensitive individual. It has been suggested 
that for those donated sera, which cause C 
activation more than four times the baseline 
level, the related human being has an elevated 
risk of HSRs development [33]. The mean level 
of SC5b-9, within four sera (for R2 and R4) was 
below four times baseline (saline) (see Figure 
4A). Therefore, one could expect that these 
donors do not carry a risk for developing 
hypersensitivity reactions in vivo. R1 and R3, 
however, showed a five- and eleven-fold 
increase in the SC5b-9 concentration, which 
means that non-PEGylated Rad-PC-Rad 
liposomes might trigger the development of 
HSRs in vivo. Our previous studies demonstrate 
that at high phospholipid concentration Pad-
PC-Pad liposomes induce weak to none 
complement activation in vitro, but no 
significant changes in the hemodynamic 
parameters, nor anaphylactic reactions were 
observed in vivo [18, 39]. 
The identification of the reactive Donor #5 
motivated further studies. Those studies 
showed that inflammatory mediators, such as 
C3a and C5a, became activated. The increased 
level of the anaphylatoxins potentially causes 
strong pro-inflammatory or anaphylactic 
responses [6, 10, 40]. Although the C3a 
concentration caused by Rad-PC-Rad 
liposomes was below three-fold the baseline 
level, the non-PEGylated liposomal samples 
were elevated significantly (P < 0.05). In 
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addition, the Rad-PC-Rad liposomes provoked 
C activation that resulted in an increased level 
of C5a anaphylatoxin. It is known that C3a and 
C5a are major contributors to the release of pro-
inflammatory cytokines [6, 9, 40]. These 
fragments serve as ligands for receptors on 
leukocytes that trigger inflammation and 
release of pro-inflammatory cytokines, 
including IL-1β, TNF-α, IL-6 and the highly 
potent chemokine IL-8 [9]. The activation of 
leukocytes with C3a and C5a is the most 
relevant property of these proteins for immune 
compatibility. C5a induces degranulation, 
chemoattraction and acts with IL-1b and TNF-
α to induce an acute immune response [10]. 
Recently, a direct link between C activation and 
the secretion of cytokines, caused by iron 
nanoparticles was presented [17]. Therefore, to 
prevent any other potential immunotoxicity in 
vivo, we studied the effect of Rad-PC-Rad 
liposomes on the production of pro-
inflammatory cytokines. 
Cytokine immunoassay 
The identification of a highly reactive donor to 
Rad-PC-Rad liposomes, as demonstrated by a 
consistently and significantly higher level of 
complement proteins and C5a anaphylatoxin 
prompted us to investigate the pro-
inflammatory response to Rad-PC-Rad. 
Measuring the cytokine release allows 
estimating the inflammatory properties of the 
tested species. To quantify the impact of Rad-
PC-Rad liposomes on cytokines’ production, 
we used isolated leukocytes and human whole 
blood. Our results obtained with whole blood 
showed differences between the two donors. 
Multiple factors have impact on the cytokine 
level, such as intra-individual differences in 
physical activity and exercising. Chronic 
exercise training results in decreased levels of 
many circulating cytokines [41]. One of the 
donors was physically active, which explains 
the reduced cytokine level. The samples R1 and 
R2 were above the negative control owing to 
the IL-12p70 production. The IL-1b level was 
below the detection limit. The results indicate 
that Rad-PC-Rad liposomes hardly cause the 
production of pro-inflammatory cytokines in 
whole blood. Liposomes induce cytokine 
production as a result of the physicochemical 
parameters, i.e. size below 100 nm, surface 
charge (cationic lipids), and hydrophobicity 
[13]. We did not observe cytokine production 
upon the positive charge. Both positively 
charged Rad-PC-Rad liposomal formulations 
R1 and R3 showed unrelated variations of the 
elevated cytokine levels. The results show no 
indication that the liposomal size plays a role in 
cytokine production. The PEG-free samples R1 
and R3 with higher mean liposome diameters 
do not lead to elevated cytokines’ production. 
In all cases the response to the liposomes 
showed levels of pro-inflammatory cytokines 
comparable to the ones of saline or R5 medium 
(see Table S6). The main causes of increased 
cytokine production, however, are unknown, as 
immunotoxicity mechanisms relate to the 
composition of nanomaterials, the cell type and 
cycle, the animal model, and the disease status. 
The biological variability may have more 
impact on the immune reaction than expected. 
The possibility that certain results are 
attributable to endotoxin contamination [42] are 
valid, even though the samples were passed 
through a sterilized filter, and experiments were 
conducted under a sterilized hood. 
IL-8 is an essential chemokine involved in the 
recruitment of neutrophils to the site of 
inflammation. More than 50% of the tested 
nanomaterials, which induce the activation of 
pro-inflammatory cytokines, caused exclusive 
production of IL-8, without inducing TNF-α 
and IL-1b. Besides, more than 50% of such 
inducers were liposomes and emulsions [15]. 
This phenomenon is not fully understood; 
however, a study suggests the involvement of 
oxidative stress [43]. 
Within the present study, the cytometric bead 
array test gave false positive results of IL-8. 
This means that the concentration of IL-8 in the 
negative and positive controls was above the 
standard concentration of the kit (see Table S6). 
Thus, we cannot conclude whether Rad-PC-
Rad liposomes induce the production of IL-8 or 
not. 
 
Precisionnanomedicine.com DOI: 10.29016/180419.2   Andover House, Andover, MA USA  
 The official Journal of CLINAM 57 
 
Figure 7. The levels of SC5b-9 (A), C4d (B), Bb (C), C3a (D), and C5a (E) complement proteins. Human sera from five 
independent donors were incubated for a period of 40 minutes at a temperature of 37 °C with saline, nitroglycerin (NTG), 
Rad-PC-Rad liposomal suspensions of selected composition (R1, R2, R3, R4), Doxil® and AmBisome®. Saline solution was 
chosen as negative control. NTG was used as another negative control. Non-PEGylated liposomal formulations caused a 
higher level of C activation, mainly via the alternative pathway. The activation of the C cascade resulted in the increased 
production of C5a anaphylatoxin. The positive control zymosan caused substantially higher levels of complement activation. 
The data are represented as mean, including error bars derived from the standard deviation among the five donors. Each 
symbol and color represent data from a single donor. Significance of differences among the groups was determined by 
ordinary one-way ANOVA, followed by Dunnett's multiple comparisons test. P-values lower than 0.05 were considered as 
statistically significant.
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Limitations of the study 
Several studies on adverse reactions, which 
were very recently published, are based on six 
or less donors [17, 31, 44]. Thus, the choice of 
six donors in the present study seems to be 
reasonable. One out of the six donors showed a 
specific behavior, which is similar to reactions 
of some individuals to liposomal drugs. 
Therefore, a substantially higher number of 
donors should be incorporated into future 
studies and the presented results have a 
preliminary character. The present results, 
however, could support the selection of the 
number of donors. In literature, one usually 
finds numbers of ten and above [32, 34, 45]. 
We hypothesize that the false positive results, 
as observed in IL-8 production originate from 
the limitations of the multiplex array system, 
which necessitates the testing of the samples at 
multiple dilutions to detect lower and higher 
abundance cytokines. Another challenge in 
cytokine detection is their short half-live, such 
as six to seven minutes for TNF-α [46]. 
Furthermore, the prepared liposomes exhibited 
a wide variety of shapes and have to be 
regarded as a mixture of spherical and non-
spherical species. Additional efforts have to be 
invested to obtain a homogeneous and uniform 
size and shape distribution. 
 
Conclusions 
The extensive research interest of nanomedicines, whether biologically derived or synthetically created, 
draws attention to their immunotoxicity. Nanometer-sized species interact with the immune system 
according to their morphology and composition. C activation and cytokine response can induce 
immune-stimulation and potentially life-threatening conditions, including anaphylaxis and cytokine 
storm. Therefore, we have carefully studied the interactions of the artificially synthesized Rad-PC-Rad 
liposomes with cellular and humoral components of the innate immune system in human blood and 
obtained promising results. In summary, the experimental results indicate that Rad-PC-Rad liposomes 
are promising shear-responsive nano-containers and related in vivo experiments could be foreseen in 
near future. 
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